- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04450706
Functional Precision Oncology for Metastatic Breast Cancer (FORESEE)
FORESEE: Functional Precision Oncology for Metastatic Breast Cancer: a Feasibility Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will enroll patients with Her2 negative (negative on immunohistochemistry or nonamplified by immunofluorescence in situ hybridization) metastatic breast cancer. Cohorts will enroll according to patient hormone receptor status as hormone receptor-positive or triple-negative. In Part 2, the trial will enroll six patients with triple-negative breast cancer and six patients with ER and/or PR receptor-positive breast cancer. Patients diagnosed with metastatic disease upfront or after a variable interval from completion of definitive therapy for local or locally advanced breast cancer will be eligible.
Patients with triple-negative metastatic breast cancer will be offered to participate in the trial at the time of diagnosis. Patients with hormone receptor-positive disease will be offered the option to participate in the study when they have exhausted endocrine monotherapy or endocrine therapeutic combinatorial options. Blood will be collected, and a biopsy will be performed prior to starting the first systemic therapy (triple-negative) or first chemotherapy (hormone receptor-positive). If enough tumor is collected, the patient will be deemed eligible for the trial. Malignant tissue collected from this biopsy will be used for genomic sequencing and for the development of organoid models for drug screening. Drugs selected for sensitivity testing will be guided by the results of the genome analysis and NCCN guidelines. Following tissue acquisition, the patient will begin therapy as selected by the treating physician. This first-line of on study therapy, either standard-of-care or investigational in the context of another existing active clinical trial, will be defined as the first "uninformed" line of therapy.
The results from the drug screening and mutation testing will be summarized and returned to the treating physicianbefore the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the "informed" line of therapy.
Patient response will be tracked for up to two uninformed lines of therapy. The first line of therapy started after the biopsy will count as the first uniformed line. If a patient does not begin an informed line of therapy after two lines of uninformed therapy they will be taken off study. Response and time of progression will be recorded on both informed and uninformed lines of therapy.
The trial will open to enrollment in two stages. Stage One will enroll three patients to assess preliminary program feasibility and to optimize the genomics pipeline and time frames. After enrollment of the first three patients, enrollment will be put on hold. Upon return of results to the treating physicians, the genomics pipeline and time frames will be evaluated. If necessary, the process will be amended to maximize pipeline efficiency and decrease the interval of time between tumor tissue acquisition and the return of results.
Stage Two will enroll 12 additional patients to further evaluate on a larger scale our functional precision oncology program in metastatic breast cancer.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Janna Espinosa
- Phone Number: 801-585-0571
- Email: janna.espinosa@hci.utah.edu
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute at University of Utah
-
Contact:
- Janna Espinosa Clinical Trials Office - Huntsman Cancer Institute at Universi
- Phone Number: 801-581-4477
- Email: Janna.Espinosa@hci.utah.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female subject aged ≥ 18 years.
- Her2 negative on immunohistochemistry or nonamplified breast cancer
Metastatic or recurrent unresectable breast cancer:
- Patient with triple-negative breast cancer without prior treatment in the metastatic setting.
- OR
- Patient with hormone receptor-positive breast cancer that has exhausted or refused all endocrine monotherapy or endocrine therapeutic combinatorial options AND has not yet been treated with chemotherapy in the metastatic settings, but for whom chemotherapy is indicated.
- Willing and capable (per treating investigator's assessment) to undergo baseline tumor collection. Tumor collection may include a solid tumor tissue sample or a fluid sample containing tumor cells.
Patient can safely undergo tumor collection:
- The tumor is reasonably accessible to tumor collection;
- The tumor is amenable to tumor collection, e.g. does not abut neurovascular structures;
- If the patient receives anticoagulation, anticoagulation can be safely withheld to accommodate for tissue acquisition;
- The patient does not have a medical condition that would render tumor acquisition a high-risk procedure, (e.g. tumor material acquisition from lung metastases in a patient with emphysema).
- Life expectancy of ≥ 6 months as assessed by the treating investigator.
- ECOG Performance Status ≤ 2.
Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
- Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have estradiol and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
- Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
- Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
- At least one lesion (measurable or non-measurable) that can be accurately assessed at baseline and is suitable for repeated assessment by computed tomography (CT), magnetic resonance imaging (MRI), plain X-ray, or physical examination.
Exclusion Criteria:
- Diagnosis of any other malignancy with a life expectancy of < 5 years.
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
- Myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (> New York Heart Association Classification Class IIB) or a serious cardiac arrhythmia requiring medication.
- Renal or liver disease that prohibits the patient from receiving at least single-agent full recommended dose chemotherapy.
The patient cannot safely undergo tumor collection for reasons including but not limited to:
- Tumor is inaccessible;
- The patient requires anticoagulation which cannot be withheld;
- The patient has bleeding diathesis;
- Any other reason that would render tumor tissue acquisition a high-risk procedure.
- Patient cannot or is unwilling to receive chemotherapy
- Known brain metastases or cranial epidural disease. Note: Brain metastases or cranial epidural disease adequately treated with radiotherapy and/or surgery and stable for at least 4 weeks before Step 1 Registration for study will be allowed on trial. Subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the Step 1 Registration for study.
- Patient's only site amenable to tumor collection to generate organoids is hepatic metastases.
Physician Inclusion Criteria
- Physician is the treating medical oncologist for a patient who meets all of the inclusion criteria and none of the exclusion criteria.
- Willing and able to answer the physician questionnaires at the protocol required time points.
- Willing and able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
Organoid Development and Tumor Material Testing Patient Eligibility
- Patient continues to meet step 1 registration criteria.
- Successful acquisition of a solid tumor biopsy sample containing ≥ 20% tumor content, or malignant fluid sample (e.g. pleural or pericardial effusion or ascites) confirmed to contain malignant cells.
- Sufficient material for Tempus commercial genomics testing and Welm lab genomics from the tumor collection; or sufficient archival tissue for Tempus and Welm lab genomics; or blood sample as allowed for liquid biopsy commercial assay.
- Sample from tumor collection is the type of sample that is feasible for organoid development as determined by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment: all patients
Blood will be collected, and a biopsy will be performed prior to starting the first systemic therapy (triple-negative) or first chemotherapy (hormone receptor-positive). If enough tumor is collected, the patient is eligible for the trial. Malignant tissue collected from this biopsy will be used for genomic sequencing and for the development of organoid models for drug screening. Drugs selected for sensitivity testing will be guided by the results of the genome analysis and NCCN guidelines. Following tissue acquisition, the patient will begin therapy as selected by the treating physician. This first-line of on study therapy, either standard-of-care or investigational in the context of another existing active clinical trial, will be defined as the first "uninformed" line of therapy. Patient response is tracked for up to two uninformed lines of therapy. The first line of the therapy started after the biopsy will count as the first uniformed line. |
The tissue from the participant sample will be used for genome sequencing and organoid establishment for drug screening.
Both solid tumor genome analysis (commercial and Welm genome) must be performed on tissue from the same biopsy.
After the biopsy, the patient will begin uninformed therapy (standard of care or investigational in the context of a separate existing active clinical trial), as selected and directed by the treating physician.
Once the results from the genome sequencing and drug screening are available, they will be returned to the treating physician.
Upon progression on the uninformed line of therapy, the patient will begin a new therapy as directed by the treating physician.
If the patient begins a therapy recommended by the precision oncology results then the next line of therapy will be deemed "informed".
While receiving the therapy, response assessments will be conducted until documented radiographic or clinical progression.
|
Experimental: Physician Questionnaire
The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy.
Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy.
If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the "informed" line of therapy.
|
The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy.
Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy.
If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the "informed" line of therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of cases where clinically actionable outcomes were identified by the use of organoids and drug screening (functional precision oncology).
Time Frame: 12 weeks
|
Determine the feasibility of comprehensive genomic characterization and drug screening for metastatic breast cancer in a clinically relevant time frame.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The time from patient sample collection to return of genomic characterization results.
Time Frame: up to 2 years
|
Time required to return genomic characterization and drug screening results to treating physicians
|
up to 2 years
|
The time from patient sample collection to return of drug screening results.
Time Frame: up to 2 years
|
Time required to return genomic characterization and drug screening results to treating physicians
|
up to 2 years
|
Performance: comparison between the number of clinically actionable outcomes identified by our functional genomic characterization and commercially available assays
Time Frame: up to 2 years
|
assess the performance and concordance of our integrated functional genomic assays (drug screen with or without genomic characterization) against commercially available assays.
|
up to 2 years
|
Concordance: To assess the frequency with which our functional precision oncology testing identifies the same therapeutic vulnerabilities identified by commercial (gold standard) testing.
Time Frame: up to 2 years
|
assess the performance and concordance of our integrated functional genomic assays (drug screen with or without genomic characterization) against commercially available assays.
|
up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Saundra Buys, MD, Huntsman Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HCI131027
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2-negative Breast Cancer
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Masonic Cancer Center, University of MinnesotaActive, not recruitingTriple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast CancerUnited States
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; iOMEDICO AGCompletedHer2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast CancerGermany
-
Fudan UniversityRecruitingBreast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)China
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
Massachusetts General HospitalGilead SciencesRecruitingTriple Negative Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast CancerUnited States
-
Cancer Trials IrelandCompletedBreast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast CancerIreland
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); Syndax PharmaceuticalsTerminatedBreast Cancer | Invasive Breast Cancer | ER-Negative PR-Negative HER2-Negative Breast CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteThe Shulas' FoundationRecruitingTriple Negative Breast Cancer | HER2-negative Breast CancerUnited States
-
German Breast GroupGilead Sciences; ETOP IBCSG Partners Foundation; UNICANCER; Austrian Breast & Colorectal... and other collaboratorsRecruitingTriple Negative Breast Cancer | HER2-negative Breast CancerSpain, France, Germany, Austria, Belgium, Ireland, Italy, Switzerland
Clinical Trials on Precision Medicine
-
Weill Medical College of Cornell UniversityRecruitingAlzheimer Disease | Mild Cognitive ImpairmentUnited States
-
Stanford UniversityRecruiting
-
University of North Carolina, Chapel HillEnrolling by invitationFrailtyUnited States
-
Karolinska University HospitalPhilips Electronics Nederland B.V. acting through Philips CTO organizationCompleted
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)Recruiting
-
Rady Pediatric Genomics & Systems Medicine InstituteEnrolling by invitation
-
Rady Pediatric Genomics & Systems Medicine InstituteRecruiting
-
Peking University Third HospitalPeking UniversityRecruitingHeart Failure | Percutaneous Coronary Intervention | Cardiometabolic Syndrome | Structural Heart AbnormalityChina
-
Boston Scientific CorporationCompletedPain | Back Pain | Chronic Pain | Pain, Intractable | Failed Back Surgery SyndromeUnited States
-
Boston Scientific CorporationTerminatedMigraineUnited Kingdom